TPBG
TVTX icon

Turning Point Benefit Group’s Travere Therapeutics TVTX Stock Holding History

Turning Point Benefit Group’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-19
Closed -$725 – 734
2025
Q4 		$725 Hold
19
– – ﹤0.01% 594
2025
Q3 		$471 Buy
+19
New +$357 ﹤0.01% 506

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Turning Point Benefit Group's TVTX Position: Q1 2026 in Review

Turning Point Benefit Group sold out of Travere Therapeutics (TVTX) in Q1 2026, closing a stake of 19 shares — an estimated $725 sold.

Turning Point Benefit Group first reported a position in TVTX in Q3 2025 and held it in 2 quarters. The position peaked at $725 in Q4 2025. 261 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Turning Point Benefit Group reported no remaining Travere Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Turning Point Benefit Group sold 19 Travere Therapeutics shares in Q1 2026, an estimated $725.
  • Turning Point Benefit Group first reported a position in Travere Therapeutics in Q3 2025 and held it in 2 quarters.
  • Turning Point Benefit Group's Travere Therapeutics position peaked at $725 in Q4 2025.
  • 261 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Turning Point Benefit Group's 13F filing for Q1 2026, filed 12 May 2026.